GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Corbus Pharmaceuticals
The shares of Corbus Pharmaceuticals, an oncology biotech, reflect the potential of its drug portfolio. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - General oncology therapy
Corbus Pharmaceuticals is a biopharmaceutical company that has shifted its focus to developing oncology drugs, leveraging its expertise in the endocannabinoid system. We classify it as a "General Oncology Therapy" company, where it is seeking its niche. The chart below shows the overall dynamics of this highly competitive sector.
Broad Market Index - GURU.Markets
Corbus Pharmaceuticals is an oncology company developing drugs that modulate the immune system to fight cancer. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
CRBP - Daily change in the company's share price Corbus Pharmaceuticals
The change_co indicator for Corbus, an oncology company, measures its high volatility. It reflects sensitivity to clinical trial results. This indicator is a key element in the formulas on System.GURU.Markets for analyzing the biotech sector.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Corbus Pharmaceuticals Holdings, Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with the dynamics of CRBP, which focuses on treating inflammatory diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Corbus Pharmaceuticals is a biotech company focused on developing drugs to treat oncology and immune diseases. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Corbus Pharmaceuticals
For Corbus Pharmaceuticals, the year-over-year performance is a story of its strategic pivot to oncology. Its market cap change over the past 12 months reflects progress in clinical trials of its new antibody-drug conjugate, a fundamental shift following the failure of its previous developments in a different area.
Annual dynamics of market capitalization of the market segment - General oncology therapy
Corbus Pharmaceuticals Holdings, Inc. is a biotech company developing drugs to treat inflammatory and fibrotic diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Corbus Pharmaceuticals is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Corbus Pharmaceuticals
Corbus Pharmaceuticals is a biotech company whose market capitalization is driven by news about clinical developments. Monthly ups and downs on the chart are directly linked to the publication of trial data. Positive results can trigger exponential growth, while trial failures immediately impact the company's valuation.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
This chart reflects the dynamics of the volatile biotech sector. For Corbus, a clinical-stage company, it's the backdrop. Its movements show how successes and failures in clinical trials, particularly in oncology, influenced investor sentiment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often live in a world of their own, where clinical trial news trumps overall market trends. The chart below shows the pulse of the broader market. Does Corbus Pharmaceuticals move in sync with it, or are breakthroughs in its R&D pipeline creating a completely independent story for the stock?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Corbus Pharmaceuticals
Corbus Pharmaceuticals shares reflect the complex and risky path of drug development every week. The price movements of this biotech company, which has shifted its focus to oncology, reflect any lab data or early clinical trial data that could confirm or refute its new direction.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Corbus Pharmaceuticals develops drugs to treat inflammatory and fibrotic diseases. For a biotech company of this profile, clinical trial data is key. The chart below shows whether Corbus's share price performance reflects unique company news or general sentiment in the oncology therapeutics sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Corbus Pharmaceuticals is a biopharmaceutical company. Its success depends on the results of clinical trials. This chart will help you understand: does Corbus live in its own world of scientific news, or are the overall market conditions and investor risk appetite in the biotech sector actually influencing its stock price?
Market capitalization of the company, segment and market as a whole
CRBP - Market capitalization of the company Corbus Pharmaceuticals
Corbus's market capitalization tells the dramatic story of a biotech company that has suffered setbacks in one area and is attempting to reinvent itself in another. The chart reflects the failure of its previous drug and its subsequent attempt to create new value through its oncology portfolio. The dynamics are a narrative of risk, resilience, and the search for a second chance.
CRBP - Share of the company's market capitalization Corbus Pharmaceuticals within the market segment - General oncology therapy
Corbus Pharmaceuticals is a biopharmaceutical company that has refocused on developing oncology drugs. Its current market capitalization reflects the market's assessment of the potential of its new programs after previous failures. This chart shows how investors assess its chances of "rebooting" and succeeding in this new field.
Market capitalization of the market segment - General oncology therapy
Corbus Pharmaceuticals is a clinical-stage biotech company focused on oncology. The chart below shows the overall market capitalization of this sector. Its dynamics reflect both the constant influx of investment in cancer drug discovery and the high risks associated with developing new drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Corbus Pharmaceuticals is a biopharmaceutical company focused on treating rare inflammatory and fibrotic diseases. Its valuation reflects the hope that its drugs will help patients for whom there are few or no treatment options. Its trajectory is a story of high risk and the potential of biotech.
Book value capitalization of the company, segment and market as a whole
CRBP - Book value capitalization of the company Corbus Pharmaceuticals
Corbus Pharmaceuticals' balance sheet represents its capital earmarked for clinical trials of a new class of drugs targeting oncology and rare diseases. This provides a tangible, scientific foundation for finding breakthrough therapeutic solutions. How has this biotech asset changed? The chart below shows its dynamics.
CRBP - Share of the company's book capitalization Corbus Pharmaceuticals within the market segment - General oncology therapy
Corbus Pharmaceuticals develops drugs to treat inflammatory diseases, which requires research laboratories. The chart shows the share of these research-intensive tangible assets, reflecting the physical foundation upon which the company conducts its scientific work.
Market segment balance sheet capitalization - General oncology therapy
Corbus Pharmaceuticals is a clinical-stage biotech company. Its value lies in its development potential, not its manufacturing facilities. A book-to-market capitalization chart will show how "light" its capital base is, which is typical for the R&D sector.
Book value of all companies included in the broad market index - GURU.Markets
Corbus Pharmaceuticals focuses on treating inflammatory diseases. The company's book value is derived from its research laboratories, clinical trial capital, and intellectual property portfolio. The chart shows the material foundation upon which the company builds its search for new therapeutic solutions.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Corbus Pharmaceuticals
Corbus Pharma's balance sheet is capital. Its market price reflects the hope for the success of its oncology drugs. The chart shows how investors' "optimism coefficient" changes with each clinical trial announcement. It's one of the purest bets on a biotech breakthrough.
Market to book capitalization ratio in a market segment - General oncology therapy
Corbus Pharmaceuticals develops drugs to treat serious inflammatory and fibrotic diseases. Its value is based on the potential of its research. This chart clearly shows how much investor expectations for future drugs exceed the company's current resources.
Market to book capitalization ratio for the market as a whole
Corbus Pharmaceuticals focuses on developing drugs targeting the endocannabinoid system to treat inflammatory and fibrotic diseases. The company's core assets are its research and development. This chart shows the overall market valuation, but how do investors evaluate a biotech company that explores a complex and poorly understood biological system?
Debts of the company, segment and market as a whole
CRBP - Company debts Corbus Pharmaceuticals
For Corbus Pharmaceuticals, a biotech company undergoing a strategic reorientation, capital management is crucial. This chart shows how the company is funding new drug development after past failures. It's a story of financial discipline and a focus on new scientific approaches.
Market segment debts - General oncology therapy
Corbus Pharmaceuticals has refocused its operations on oncology drug development. This strategic shift and the launch of new clinical programs require fresh capital. This chart shows how the company is funding its new strategy and how its financial structure is typical for biotech companies undergoing transformation.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Corbus Pharmaceuticals
Corbus Pharmaceuticals is a biotech company focused on developing therapies for oncology and inflammatory diseases. This chart shows how heavily the company relies on debt to finance its research. It's a classic biotech story: debt fueling high-risk, high-reward scientific breakthroughs.
Market segment debt to market segment book capitalization - General oncology therapy
Corbus Pharmaceuticals focuses on developing drugs to treat rare inflammatory and fibrotic diseases. This chart shows the overall debt burden in the biotech sector. It helps understand how the industry as a whole finances its risky clinical trials and how Corbus, following its shift in strategy, manages its capital.
Debt to book value of all companies in the market
Corbus Pharmaceuticals is searching for new cancer treatments. Like many research-stage biotechs, the company has virtually no debt, and its survival depends on investor confidence. This chart, reflecting the market's leverage, vividly illustrates the contrast between speculative biotech and stable, cash-generating sectors.
P/E of the company, segment and market as a whole
P/E - Corbus Pharmaceuticals
This chart for Corbus Pharmaceuticals illustrates investor expectations for drug development. Like many biotech companies, its value is based not on current profits, but on the company's research potential. It's an estimate of future breakthroughs in the treatment of serious diseases, coupled with a high risk of clinical failure.
P/E of the market segment - General oncology therapy
Developing drugs for rare diseases, as Corbus does, is a high-risk business. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Corbus, after its shift in strategy, is being valued based on the potential of its new scientific pipeline, not on past failures.
P/E of the market as a whole
Corbus Pharmaceuticals has refocused its operations on oncology drug development. Such strategic shifts take time to bear fruit. This chart, reflecting sentiment in the biotech sector, helps us understand how much investors believe in the company's new strategy and whether they are willing to fund its research given the overall market situation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Corbus Pharmaceuticals
Corbus Pharmaceuticals is a biotech company refocusing on oncology. This chart reflects investor expectations for its new clinical programs. The dynamics show how the market views the potential of its acquired assets and its ability to succeed in the highly competitive field of cancer drug development.
%20P%2FE%20Corbus%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Corbus-Pharmaceuticals&v=1772513868010 "Chart of the company's future (projected) P/E Corbus Pharmaceuticals")
Future (projected) P/E of the market segment - General oncology therapy
Corbus Pharmaceuticals is focused on developing drugs for the treatment of oncology and fibrotic diseases. This chart shows the average profitability expectations for the sector. It provides insight into how the market views the company's current clinical programs after previous failures and its chances of success with new candidates.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772513868066 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of oncology and fibrotic diseases. This chart shows investors' risk appetite. For a company whose future revenue depends on the success of clinical trials, it reflects the overall market's willingness to finance long-term and risky scientific development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513868114 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Corbus Pharmaceuticals
Corbus Pharmaceuticals is a clinical-stage biotechnology company focused on treating serious inflammatory and fibrotic diseases. The financial result shown here represents net clinical trial expenses. The chart illustrates the long and expensive process of drug development for complex and difficult-to-treat diseases.
Profit of companies in the market segment - General oncology therapy
Corbus Pharmaceuticals is a biopharmaceutical company focused on the treatment of serious inflammatory and fibrotic diseases. Its research focuses on modulating the endocannabinoid system. This chart reflects the high risk and potential rewards of biotechnology, where the discovery of new therapeutic targets can lead to the development of breakthrough drugs.
Overall market profit
Corbus Pharmaceuticals is a biotech company that has refocused its research on oncology. Like many companies in clinical development, its survival and success depend on its ability to attract funding. The strong economic environment, reflected in this chart, creates favorable capital market conditions for supporting such risky but potentially important projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Corbus Pharmaceuticals
Corbus Pharmaceuticals is a clinical-stage oncology company developing drugs to treat serious diseases. The profit/loss projections in this chart reflect high R&D costs. The curve's dynamics reflect analysts' expectations for clinical trial results and the company's R&D pipeline.
%20profit%20of%20the%20company%20Corbus%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Corbus-Pharmaceuticals&v=1772513868222 "Graph of future (projected) profit of the company Corbus Pharmaceuticals")
Future (predicted) profit of companies in the market segment - General oncology therapy
Corbus Pharmaceuticals develops drugs targeting the endocannabinoid system to treat inflammatory and fibrotic diseases. This is an innovative therapeutic approach. This chart shows revenue projections for the oncology and therapeutics sectors, providing context for assessing the potential of Corbus's unique scientific approach relative to the broader pharmaceutical industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772513868293 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Corbus Pharmaceuticals is a clinical-stage biotech company. Its value is determined by the potential of its drugs in development, not by current revenue. However, the overall market situation, reflected in this chart, significantly impacts the ability of such companies to attract funding to continue research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513868309 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Corbus Pharmaceuticals
Corbus Pharmaceuticals is a biotech company refocusing on oncology. This chart shows how investors value its revenue during this transformation. This valuation reflects confidence in the potential of its new assets and the team's ability to successfully execute its new strategy in a highly competitive field.
P/S market segment - General oncology therapy
Corbus Pharmaceuticals is a biopharmaceutical company focused on developing a new class of drugs targeting the immune system for the treatment of cancer and inflammatory diseases. This chart shows the industry average market capitalization to revenue ratio. It reflects investor expectations for the company's clinical trials and the potential of its scientific platform.
P/S of the market as a whole
Corbus Pharmaceuticals is a biopharmaceutical company focused on developing immunotherapeutic drugs for the treatment of cancer. The company is developing a portfolio of assets targeting various tumor-fighting mechanisms. This chart helps understand how the market values clinical-stage biotech companies in the competitive field of oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Corbus Pharmaceuticals
Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating serious inflammatory and fibrotic diseases. This chart shows its valuation relative to projected future sales. It reflects investor expectations for positive clinical trial results from its lead candidates.
%20P%2FS%20Corbus%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Corbus-Pharmaceuticals&v=1772513868421 "The graph of the company's future (projected) P/S Corbus Pharmaceuticals")
Future (projected) P/S of the market segment - General oncology therapy
Corbus Pharmaceuticals is focused on developing precision oncology drugs targeting rare and aggressive forms of cancer. The company's future depends on the success of its clinical programs. This metric demonstrates how investors view its scientific approach and future revenue potential compared to other oncology companies.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772513868438 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Corbus Pharmaceuticals is a clinical-stage biotech focused on treating serious diseases. Its value is determined by the potential of its developments. This graph of overall expectations for CRBP is a baseline. The company's success depends on research results, not the overall economic climate, and could create its own strong trend.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513868459 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Corbus Pharmaceuticals
This chart illustrates the financial path of a biopharmaceutical company during clinical development. For Corbus Pharmaceuticals, it reflects revenue from partnerships and funding for the development of its drug candidates. Significant changes will occur with successful clinical trials and commercialization.
Sales of companies in the market segment - General oncology therapy
Corbus Pharmaceuticals develops drugs to treat serious inflammatory and fibrotic diseases. Being in the clinical stage, it influences expectations in the sector. This chart reflects revenue in oncology, and the potential success of Corbus's drugs in maintenance therapy could create a new market and significantly contribute to overall revenue.
Overall market sales
Corbus Pharmaceuticals is a biotechnology company focused on developing drugs to treat serious inflammatory and fibrotic diseases. Its success depends on the results of clinical trials. The company's activities are part of a vast innovation ecosystem in healthcare, which is increasingly contributing to the country's GDP.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Corbus Pharmaceuticals
Corbus Pharmaceuticals develops drugs to treat serious inflammatory and fibrotic diseases. Its future sales forecast is entirely dependent on the clinical trial results of its lead candidates. This graph reflects the high risks and potential of a biotech company in the development stage.
%20sales%20of%20the%20company%20Corbus%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Corbus-Pharmaceuticals&v=1772513868666 "Schedule of future (projected) sales of the company Corbus Pharmaceuticals")
Future (projected) sales of companies in the market segment - General oncology therapy
Corbus Pharmaceuticals develops drugs to treat serious inflammatory and fibrotic diseases. The forecast for the oncology and therapeutic sectors reflects general expectations and allows us to assess the potential market for the company's innovative approaches targeting complex biological targets.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772513868691 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Corbus Pharmaceuticals is a clinical-stage biotech focused on treating serious inflammatory and fibrotic diseases. Its prospects depend on the success of its clinical programs. This overall economic activity schedule does not impact patient demand for treatment, but it may influence overall investor risk appetite in the biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513868717 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Corbus Pharmaceuticals
Corbus Pharmaceuticals is a clinical-stage oncology company. Its financial performance is focused on R&D expenses for its drug portfolio. This chart shows not current profit, but rather the capital burn rate, a key metric for biotech companies seeking to bring a new product to market.
Market segment marginality - General oncology therapy
Corbus Pharmaceuticals has refocused its operations on oncology drug development. Its financial performance reflects this transformation and its focus on clinical research. This chart provides insight into the company's operating model and cost structure compared to other companies operating in the general oncology field.
Market marginality as a whole
Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating rare and serious inflammatory diseases. This chart shows the company's overall profit margin. In contrast, Corbus is a venture capital investment in science. Its financial metrics reflect the capital burned on research, and future profitability depends on clinical success.
Employees in the company, segment and market as a whole
Number of employees in the company Corbus Pharmaceuticals
Corbus Pharmaceuticals is a biotech company focused on treating rare diseases and oncology. Its staff consists primarily of scientists and clinicians. The dynamics in this chart reflect its trajectory: growth may be due to the advancement of a key drug in trials, while layoffs may be due to restructuring following trial failures.
Share of the company's employees Corbus Pharmaceuticals within the market segment - General oncology therapy
Corbus Pharmaceuticals develops drugs targeting the endocannabinoid system to treat inflammatory and fibrotic diseases. This chart highlights its scientific focus. It reflects the proportion of scientists and researchers specializing in this complex and promising area of pharmacology that Corbus is engaging to develop new classes of drugs.
Number of employees in the market segment - General oncology therapy
Corbus Pharmaceuticals develops drugs to treat serious inflammatory and fibrotic diseases. This graph reflects the long and risky path of drug discovery. The dynamics of the number of scientists and clinicians here is an indicator of the clinical trial phase, which determines the company's future and patients' hopes.
Number of employees in the market as a whole
Corbus Pharmaceuticals develops drugs to treat rare inflammatory diseases. This overall workload schedule has little impact on the company, whose success depends on breakthroughs in the laboratory. Their life cycle is determined by the phases of clinical trials. Success in one phase can lead to a sharp increase in the research staff, regardless of the economic situation.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals is a biopharmaceutical company focused on treating rare inflammatory diseases. Its value lies in its pipeline. This chart clearly demonstrates how the market values biotech innovations. The high market capitalization per scientist reflects the potential value of future drugs, not current sales.
%20of%20the%20company%20Corbus%20Pharmaceuticals%20(CRBP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Corbus-Pharmaceuticals-CRBP&v=1772513869031 "Chart of market capitalization per employee (in thousands of dollars) of the company Corbus Pharmaceuticals (CRBP)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Corbus Pharmaceuticals develops drugs to treat inflammatory diseases. As with other biotech companies, the company's market capitalization outpaces its current revenue and headcount. This chart reflects investors' faith in the scientific potential of a small team capable of creating a blockbuster and generating billions in revenue, which drives high employee valuations.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772513869051 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Corbus Pharmaceuticals develops drugs targeting the endocannabinoid system to treat inflammatory and fibrotic diseases. This chart reflects the high valuation per employee typical of biotech companies, where a company's value is determined by the potential of its unique scientific approach to developing new classes of drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513869055 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals is a biotech company focused on treating serious immune and oncological diseases. It is an R&D company in the clinical trials stage. Its main asset is intellectual property. This indicator will be negative. It demonstrates how much the company invests in each scientist and employee to advance its drug candidates through costly trials.
%20Chart%20Corbus%20Pharmaceuticals%20(CRBP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Corbus-Pharmaceuticals-CRBP&v=1772513869078 "Company Profit Per Employee (in thousands of dollars) Chart Corbus Pharmaceuticals (CRBP)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Corbus Pharmaceuticals is a clinical-stage company focused on treating inflammatory and fibrotic diseases. This chart shows the industry standard, which is still theoretical for CRBP. The company generates losses during the R&D phase. Its goal is to prove the efficacy of its drugs so that its profitability per intellectual property manager (IPM) can soar above the benchmark.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772513869105 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Corbus Pharmaceuticals develops drugs for the treatment of inflammatory and fibrotic diseases. It is a biotech company in the clinical trial stage. Its entire staff consists of scientists and administrative personnel working on future products. Negative profit per employee is the norm here. The graph illustrates the "cost" of the R&D team waiting for successful trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513869135 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals is a clinical-stage biotech company. This chart shows that its focus is on research and development, not sales. Lack of revenue is the norm. This metric demonstrates potential: a successful drug can generate enormous revenue, leading to explosive growth in revenue per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Corbus-Pharmaceuticals-CRBP&v=1772513869246 "Sales chart per company employee Corbus Pharmaceuticals (CRBP)")
Sales per employee in the market segment - General oncology therapy
Corbus Pharmaceuticals is a biotech company refocused on developing cancer drugs. At the clinical trial stage, this metric reflects how effectively their research team generates revenue (e.g., from partnerships) per employee, which is critical for funding expensive R&D.
Sales per employee for the market as a whole
Corbus Pharmaceuticals is a clinical-stage biotech company focused on treating oncology and fibrotic diseases. This chart shows revenue per employee. Since the company has no commercial products, this figure is likely zero. It clearly demonstrates that the company's business is 100% R&D, with its in-house scientists working on future drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals is a biotech company focused on developing drugs for serious inflammatory and fibrotic diseases. This chart shows bearish sentiment. Bears may be betting on the failure of its key drugs in clinical trials, a common occurrence in this industry and a major risk for investors.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Corbus-Pharmaceuticals-CRBP&v=1772513869459 "Short Shares Chart for the Company Corbus Pharmaceuticals (CRBP)")
Shares shorted by market segment - General oncology therapy
Corbus Pharmaceuticals develops drugs to treat serious inflammatory and fibrotic diseases. This chart shows overall short positions in the biotech sector. A high chart reflects general market skepticism about the sector, possibly due to fears of research failures or tightening regulatory policies (e.g., the FDA) across the sector.
Shares shorted by the overall market
Corbus Pharma (CRBP) is a clinical-stage biotech. Its value reflects the hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse that require constant refinancing for R&D, and CRBP is caught in the middle of this sell-off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals is a clinical-stage biotech. The stock is highly speculative. This chart can surge above 70 on positive R&D news. Oversold levels (<30) often reflect research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Corbus-Pharmaceuticals-CRBP&v=1772513869769 "RSI 14 indicator chart for the company's stock Corbus Pharmaceuticals (CRBP)")
RSI 14 Market Segment - General oncology therapy
Corbus (CRBP) is a biotech company focused on *oncology* and immunology. The RSI_14_Seg for "General Oncology Therapy" (biotech) shows the overall sentiment. The chart helps us understand: is CRBP's volatility a reaction to its clinical trials, or is the *entire* biotech sector "overheated" (or "oversold")?
RSI 14 for the overall market
Corbus Pharmaceuticals (CRBP) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CRBP (Corbus Pharmaceuticals)
Corbus Pharmaceuticals is a biotech company developing drugs for the treatment of oncology and inflammatory diseases. This chart shows the average 12-month analyst forecast. Their target price depends entirely on the interpretation of clinical trial data and the assessment of the chances of approval of their drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CRBP-Corbus-Pharmaceuticals&v=1772513869860 "A chart showing analyst consensus forecasts for the expected stock price. CRBP (Corbus Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price CRBP (Corbus Pharmaceuticals)
Corbus Pharmaceuticals (CRBP) is a clinical-stage oncology company. This chart is a classic barometer of biotech hopes. It measures the vast gap between the current speculative price and the analyst consensus price target. This gap reflects the enormous, yet risky, potential experts believe lies in the success of their R&D.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CRBP-Corbus-Pharmaceuticals&v=1772513869884 "A chart showing the difference between the consensus forecast and the actual stock price. CRBP (Corbus Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Corbus Pharmaceuticals is a biotech company that, after previous setbacks, has refocused on developing a new class of oncology drugs (antibody-drug conjugates, ADCs). This chart shows analysts' overall expectations for the entire oncology sector. It reflects whether experts believe in R&D breakthroughs in this complex field.
Analysts' consensus forecast for the overall market share price
Corbus Pharmaceuticals is a biotech company that has shifted focus and is now developing drugs (antibodies) for cancer treatment. This chart shows the overall risk appetite. For Corbus, a high-risk clinical-stage company, overall market optimism is critical to raising the capital needed to fund lengthy and expensive clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Corbus Pharmaceuticals
Corbus Pharmaceuticals is a clinical-stage biotech focused on developing next-generation cancer treatments (including ADCs). It's a high-risk business, betting on science. This chart is a pure indicator of faith in their R&D. It doesn't reflect current sales (they don't have any), but rather a speculative assessment of their scientific progress, clinical trial data, and chances of approval.
AKIMA Market Segment Index - General oncology therapy
Corbus Pharmaceuticals is a biotech company that has refocused its efforts on developing immuno-oncology drugs. This is a high-risk business with potential for breakthroughs. This chart shows the average index for the oncology sector. It provides investors with a benchmark for how Corbus's overall performance compares to the sector average.
The AKIM Index for the overall market
Corbus Pharmaceuticals is an oncology company developing precision drugs (ADCs) for the treatment of solid tumors. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this scientific company, competing in the hot ADC segment, stacks up against overall economic trends.
